» Authors » Peter Madsen

Peter Madsen

Explore the profile of Peter Madsen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 338
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wathen C, Punchak M, Madsen P, Vaughan K, Buch V, Marcotte P
World Neurosurg X . 2024 Mar; 23:100295. PMID: 38497062
No abstract available.
2.
Lang S, Kumar N, Madsen P, Gajjar A, Gajjar E, Resnick A, et al.
Cancer Genet . 2022 Feb; 262-263:64-70. PMID: 35108662
Neurotrophins and their related tyrosine kinase receptors (TRKs), encoded by the neurotrophic tyrosine receptor kinase genes NTRKs, play a crucial role in central nervous system development. Oncogenic NTRK gene fusion...
3.
Tagmose T, Pedersen K, Pridal L, Stidsen C, Pedersen M, Lin Z, et al.
J Med Chem . 2022 Feb; 65(3):2633-2645. PMID: 35104142
Here, we describe molecular engineering of monovalent ultra-long acting two-chain insulin-Fc conjugates. Insulin-Fc conjugates were synthesized using trifunctional linkers with one amino reactive group for reaction with a lysine residue...
4.
Nishimura E, Pridal L, Glendorf T, Hansen B, Hubalek F, Kjeldsen T, et al.
BMJ Open Diabetes Res Care . 2021 Aug; 9(1). PMID: 34413118
Introduction: Insulin icodec is a novel, long-acting insulin analog designed to cover basal insulin requirements with once-weekly subcutaneous administration. Here we describe the molecular engineering and the biological and pharmacological...
5.
Hubalek F, Refsgaard H, Gram-Nielsen S, Madsen P, Nishimura E, Munzel M, et al.
Nat Commun . 2021 Jul; 11(1):4232. PMID: 34244486
No abstract available.
6.
Kurtzhals P, Nishimura E, Haahr H, Hoeg-Jensen T, Johansson E, Madsen P, et al.
Trends Pharmacol Sci . 2021 Jun; 42(8):620-639. PMID: 34148677
The life-saving discovery of insulin in Toronto in 1921 is one of the most impactful achievements in medical history, at the time being hailed as a miracle treatment for diabetes....
7.
Kjeldsen T, Hubalek F, Hjorringgaard C, Tagmose T, Nishimura E, Stidsen C, et al.
J Med Chem . 2021 May; 64(13):8942-8950. PMID: 33944562
Here, we describe the molecular engineering of insulin icodec to achieve a plasma half-life of 196 h in humans, suitable for once-weekly subcutaneously administration. Insulin icodec is based on re-engineering...
8.
Kjeldsen T, Hubalek F, Tagmose T, Pridal L, Refsgaard H, Porsgaard T, et al.
J Med Chem . 2020 Dec; 64(1):616-628. PMID: 33356257
Recently, the first basal oral insulin (OI338) was shown to provide similar treatment outcomes to insulin glargine in a phase 2a clinical trial. Here, we report the engineering of a...
9.
Dimentberg R, Kvint S, Madsen P, Glauser G, Choudhri O
World Neurosurg . 2020 Oct; 146:14. PMID: 33080403
This case video demonstrates a microsurgical technique for the clipping and obliteration of a Cognard V tentorial dural fistula (Video 1). The patient was a 49-year-old male who presented with...
10.
Hubalek F, Refsgaard H, Gram-Nielsen S, Madsen P, Nishimura E, Munzel M, et al.
Nat Commun . 2020 Jul; 11(1):3746. PMID: 32719315
Recently, the clinical proof of concept for the first ultra-long oral insulin was reported, showing efficacy and safety similar to subcutaneously administered insulin glargine. Here, we report the molecular engineering...